BRD4 is inversely correlated with miR-29b in CTCL. (A) Relative expression of miR-29b in peripheral blood CD4⁺ T cells from CTCL patients (n = 9) and normal donors (n = 6). (B) Sequence alignment of the mature miR seed sequence of miR-29b showing complementarity to the 3′UTR of BRD4. (C) Immunoblot analysis of BRD4 protein in splenocytes from miR-29b^−/− and age-matched WT mice (n = 4 each). (D) RT-PCR analysis for pri-miR-29b1 in CTCL-derived CD4⁺ T-cell lines treated with 10 nM bortezomib showing a significant increase in pri-miR-29b1 level after 3 hours. Data are presented as mean ± standard error of the mean (SEM) (n = 3 each). (E) Immunoblot of BRD4 protein expression in CTCL-derived CD4⁺ T-cell lines treated with 50 nM bortezomib for 24 hours showing decreased expression in treated cells compared with dimethyl sulfoxide–treated controls. Data are presented as mean ± standard error of the mean (SEM). *P ≤ .05; **P ≤ .01; ***P ≤ .001; ****P ≤ .0001; unpaired 2-tailed Student t test. ns, not significant.